Keywords
Laser
Steroids
AntiVEGFS
Macular oedema
Categories
How to Cite
Abstract
Introduction: Branch Retinal Vein Occlusion (BRVO) is the second most common retinal vascular disease with a
prevalence of 0.8%. The Branch Vein Occlusion Study was the first trial to show efficacy of treatment of macular
oedema in BRVO with grid laser which was considered the gold standard for several years. Since then several
other studies have been done on various classes of drugs and surgery and there are great strides that have
been made in enhancing the visual and anatomical outcome. In this review article, we did a pubmed search of
publications done over the years on the natural history of BRVO as well as the treatment options. The studies
included clinical trials, systematic reviews and case reports.
Results: Currently anti-Vascular Endothelial Growth Factors (AntiVEGFs) appear to have the best outcomes in
terms of anatomical and visual recovery. Other therapies that have shown promise are the intravitreal steroids,
grid laser, antiVEGFs and steroids combined with lasers. Parsplana vitrectomy appears to be as efficacious as
antiVEGF but is very invasive and no good clinical trials have been done yet.
Conclusion: Great strides have been made in improving the outcome of BRVO especially the macular oedema if
prompt and correct treatment is administered to the patient.
References
Lam FC, Chia SN, Lee RM. Macular grid laser
photocoagulation for branch retinal vein occlusion.
Cochrane Database Syst Rev. 2015; 5:CD008732.
Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj
N, Rundle AC, et al. Ranibizumab for macular
edema following branch retinal vein occlusion: Sixmonth
primary end point results of a phase III study.
Ophthalmology. 2010; 117(6):1102-12.
Rehak, J. Branch retinal vein occlusion: pathogenesis,
visual prognosis, and treatment modalities. Curr Eye
Res. 2008; 33(2): 111–131.
Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of
plasma homocysteine, serum folate, serum vitamin
B12, and thermolabile MTHFR genotype as risk
factors for retinal vascular occlusive disease. Am J
Ophthalmol. 2003; 136(6):1136–1150.
Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N,
et al. Natural history of branch retinal vein occlusion:
an evidence-based systematic review. Ophthalmology.
; 117: 1094–1101. [PubMed: 20430447]
Hayreh S. Ocular vascular occlusive disorders:
Natural history of visual outcome. Prog Retin Eye
Res. 2014; 4: 1–25.
Hayreh S, Zimmerman B. Fundus changes in branch
retinal vein occlusion. Retina. 2015; 35(5):1016–1027
The Branch Vein Occlusion Study Group: Argon laser
photocoagulation for macular edema in branch vein
occlusion. Am J Ophthalmol. 1984; 98(3):271-282.
Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi
BA, Fisher M, et al. A randomized trial comparing
the efficacy and safety of intravitreal triamcinolone
with standard care to treat vision loss associated
with macular edema secondary to branch retinal vein
occlusion: The Standard Care vs Corticosteroid for
Retinal Vein Occlusion (SCORE) study report 6.
Arch Ophthalmol. 2009; 127(9):1115-28.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS,
Gillies M, et al. Dexamethasone intravitreal implant
in patients with macular edema related to branch or
central retinal vein occlusion twelve-month study
results. Ophthalmology. 2011; 118(12):2453-60.
Hikichi T, Higuchi M, Matsushita T, Kosaka S,
Matsushita R, Takami K, et al. Two-year outcomes of
intravitreal bevacizumab therapy for macular oedema
secondary to branch retinal vein occlusion. Br J
Ophthalmol. 2014; 98(2):195-199.
Rush RB, Simunovic MP, Aragon AV, Ysasaga JE.
Treat-and-extend intravitreal bevacizumab for branch
retinal vein occlusion. Ophthalmic Surg Lasers
Imaging Retina. 2014; 45(3):212-216.
Guignier B, Subilia-Guignier A, Fournier I, Ballonzoli
L, Speeg-Schatz C, Gaucher D. Prospective pilot
study: Efficacy of intravitreal dexamethasone and
bevacizumab injections in the treatment of macular
oedema associated with branch retinal vein occlusion.
Ophthalmologica. 2013; 230(1):43-49.
Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-
Schmidt KU, Jaissle GB. Grid laser photocoagulation
for macular oedema due to branch retinal vein
occlusion in the age of bevacizumab? Results of
a prospective study with crossover design. Br J
Ophthalmol. 2013; 97(2):215-219.
Brown DM, Campochiaro PA, Bhisitkul RB, Ho
AC, Gray S, Saroj N, et al. Sustained benefits from
ranibizumab for macular edema following branch
retinal vein occlusion: 12-month outcomes of a phase
III study. Ophthalmology. 2011; 118(8):1594-1602.
Campochiaro PA, Clark WL, Boyer DS, Heier JS,
Brown DM, Vitti R, et al. Intravitreal aflibercept
for macular edema following branch retinal vein
occlusion: The 24-week results of the VIBRANT
study. Ophthalmology. 2015; 122(3):538-544.
Clark WL, Boyer DS, Heier JS, Brown DM, Haller
JA, Vitti R, et al. Intravitreal aflibercept for macular
edema following branch retinal vein occlusion: 52-
week results of the VIBRANT study. Ophthalmology.
; 123(2):330-336.
Houtsmuller JA, Vermeulen M. Klompe, et al. The
influence of ticlopidine on the natural course of
retinal vein occlusion. Agents Actions Suppl. 1984;
: 219-229.
Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A,
Lelong F, Samama MM. A randomized, doublemasked
study on the treatment of retinal vein
occlusion with troxerutin. Amer J Ophthalmol. 1994;
(4): 421-429.
Murakami T, Takagi H, Kita M, et al. Intravitreal
tissue plasminogen activator to treat macular edema
associated with branch retinal vein occlusion. Amer J
Ophthalmol. 2006; 142(2): 318-320.
Hattenbach LO, Steinkamp G, Scharrer I, Ohrloff
C. Fibrinolytic therapy with low dose recombinant
tissue plasminogen activator in retinal vein occlusion.
Ophthalmologica. 1998; 212(6): 394-398.
Lazo-Langner A, Hawel J, Ageno W, Kovacs MJ.
Low molecular weight heparin for the treatment of
retinal vein occlusion: a systematic review and metaanalysis
of randomized trials. Haematologica. 2010;
(9): 1587–1593.
Ageno W, Cattaneo R, Manfredi E, et al. Parnaparin
versus aspirin in the treatment of retinal vein
occlusion. A randomized, double blind, controlled
study. Thrombosis Res. 2010; 125(2): 137–141.
Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M,
Arimura S, Takihara Y, et al. Comparative study of
combined bevacizumab/targeted photocoagulation vs
bevacizumab alone for macular oedema in ischaemic
branch retinal vein occlusions. Acta Ophthalmol.
; 94(6): e225-230.
Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon
S, Zimmer-Galler I, et al. Scatter photocoagulation
does not reduce macular edema or treatment burden
in patients with retinal vein occlusion: The RELATE
Trial. Ophthalmology. 2015; 122(7):1426-1437.
Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb
C, Junker B, et al. Ranibizumab for Branch Retinal
Vein Occlusion Associated Macular Edema Study
(RABAMES): Six-month results of a prospective
randomized clinical trial. Acta Ophthalmol. 2015;
(1):e29.
Azad SV, Salman A, Mahajan D, Sain S, Azad R.
Comparative evaluation between ranibizumab
combined with laser and bevacizumab combined
with laser versus laser alone for macular oedema
secondary to branch retinal vein occlusion. Middle
East Afr J Ophthalmol. 2014; 21(4):296-301.
Lam FC, Chia SN, Lee RM. Macular grid laser
photocoagulation for branch retinal vein occlusion.
Cochrane Database Syst Rev. 2015; 5:CD008732.
Adelman RA, Parnes AJ, Bopp S, Saad Othman I,
Ducournau D. Strategy for the management of macular
edema in retinal vein occlusion: The European Vitreo
Retinal Society Macular Edema study. Biomed Res
Int. 2015; 2015:870987